Glenmark Pharmaceutical unit gets approval for Lithium Carbonate Tablets
Glenmark Generics Inc. USA (GGI), a subsidiary of Glenmark Pharmaceutical, has received ANDA approval from the United States Food and Drug Administration (U. S. FDA) for Lithium Carbonate 150 mg, 300 mg and 600 mg capsules.
The company plan to immediately commence marketing and distribution of these products in the U. S. Market.
Lithium is indicated in the treatment of manic episodes of Bipolar Disorder. It is also indicated as a maintenance treatment for individual with a diagnosis of Bipolar Disorder.
According to IMS Health, Lithium Carbonate capsules had annual sales of USD 10 million for the period ending September 2008.
Glenmark's current portfolio consists of 38 generic products authorized for distribution in the U. S. market. The company currently has over 40 ANDA's filed with the U. S. FDA pending approval.
Today, the scrip of the company settled the day at Rs 121 on BSE, down 8% compared to previous close of Rs 131.






